OMDA

AI Memo

Omada Health

As of 2026-09-12/Confidence medium/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-12 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

6‑12m

Key catalyst

Planned CEO transition • 2027-01-01

Base target: $24 / p=45% prob

Biggest risk

The Investor Day targets are long-dated aspirations rather than near-term guidance, with adjusted EBITDA margin still far below the 30% goal. OMDA fell 8.6% on September 11 after the event, suggesting elevated expectations or concern about the execution horizon, although the price move alone does not establish causation. Customer and channel concentration, enrollment conversion, competitive pressure, and leadership-transition execution remain material risks.

Invalidation

Break below $15 or thesis failure.

What would change my mind?

Q2 revenue increased 43% to $88 million, gross margin reached 73%, adjusted EBITDA was $11 million, and membership rose 45%, demonstrating simultaneous growth and operating leverage [#SEC-8K-2026-08-06]. Investor Day added at least 20% long-term revenue growth and substantially higher margin targets [#IR-2026-09-10]. Barclays subsequently raised its target to $27 from $25 while retaining an Overweight rating.

Research note

Recommendation

—

Confidence

medium

As of

2026-09-12

Base target

$24

p=45%

Bull target

$30

p=25%

Bear target

$15

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Multi-condition platform commercialization
Execution against new Investor Day targets
Q2 revenue increased 43% to $88 million, gross margin reached 73%, adjusted EBITDA was $11 million, and membership rose 45%, demonstrating simultaneous growth and operating leverage [#SEC-8K-2026-08-06].

BearKey bullets

Growth depends on converting covered lives into enrolled and engaged members while maintaining customer and channel-partner relationships; concentration and renewal risk remain material [#IR-2026-09-10].
Long-term targets require roughly 10 percentage points of additional non-GAAP gross-margin expansion and a substantial increase from the current 7% adjusted EBITDA margin [#IR-2026-09-10].
Recent open-market sales by incoming CEO Wei-Li Shao and outgoing CEO Sean Duffy are a modest sentiment overhang but do not establish deterioration in operating performance [#SEC-FORM4-2026-09-04] [#SEC-FORM4-2026-09-03].

WatchKey bullets

Planned CEO transition

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $24 (p=45%)

Target spread vs base: +25% / -37%

Scenario probabilities

Bull Target: $30 (p=25%)Base Target: $24 (p=45%)Bear Target: $15 (p=30%)

Commentary

Primary-source news is constructive: strong Q2 growth and profitability were followed by higher long-term margin targets [#SEC-8K-2026-08-06] [#IR-2026-09-10]. Barclays' post-event target increase is supportive, but OMDA's 8.6% September 11 decline indicates that the market response was materially less favorable than the headlines. Social coverage is unavailable, and the zero values for social sentiment, options skew, short interest, and employee rating represent unavailable data rather than neutral readings. Insider sales add a modest counter-signal [#SEC-FORM4-2026-09-04] [#SEC-FORM4-2026-09-03].

As of 2026-09-12 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Multi-condition platform commercialization
Execution against new Investor Day targets

Scenarios

Bull Target (Scenario probability)

$30 / p=25% prob

Base Target (Scenario probability)

$24 / p=45% prob

Bear Target (Scenario probability)

$15 / p=30% prob

Analysis 2026-09-12 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.25

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2027-01-01
Planned CEO transition
President Wei-Li Shao is scheduled to become CEO on January 1, 2027, while founder Sean Duffy moves to Executive Chair. The planned continuity limits immediate disruption, but commercial execution and accountability through the handoff remain monitoring points [#SEC-8K-2026-08-06].
Prob 90.00% • Move 5.00% • Priced-in 70.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

Multi-condition platform commercialization
2027-06-30
Q2 members increased 45% year over year, HCSC expansion added access to 1.5 million covered lives, cholesterol management launched with a large retailer, and the first prescribing-program customer is expected to contribute revenue in 2027. Conversion of covered lives into engaged, revenue-generating members is the key proof point [#SEC-8K-2026-08-06].
Prob 65% • Move 10% • Priced-in 50%
Execution against new Investor Day targets
2027-12-31
Omada established long-term targets of at least 20% annual revenue growth, 80% non-GAAP gross margin, and 30% adjusted EBITDA margin. Delivery depends on covered-life growth, enrollment, engagement, product mix, AI-enabled automation, and operating leverage; the large gap from the current 70% non-GAAP gross margin and 7% adjusted EBITDA margin makes execution evidence more important than the targets themselves [#IR-2026-09-10].
Prob 55% • Move 12% • Priced-in 55%

Risks

Growth depends on converting covered lives into enrolled and engaged members while maintaining customer and channel-partner relationships; concentration and renewal risk remain material [#IR-2026-09-10].
Long-term targets require roughly 10 percentage points of additional non-GAAP gross-margin expansion and a substantial increase from the current 7% adjusted EBITDA margin [#IR-2026-09-10].
Recent open-market sales by incoming CEO Wei-Li Shao and outgoing CEO Sean Duffy are a modest sentiment overhang but do not establish deterioration in operating performance [#SEC-FORM4-2026-09-04] [#SEC-FORM4-2026-09-03].
The January 2027 CEO transition introduces execution and key-person risk despite the planned founder continuity [#SEC-8K-2026-08-06].

Peers

Symbol	Summary
ATEC	Similar-market-cap healthcare-equipment company, but its spine-device business has materially different demand, reimbursement, and product-cycle drivers; useful only as a broad growth-company reference.
CNMD	Similar-market-cap medical-device company with hospital and procedural exposure that differs substantially from Omada's virtual chronic-care model; not a direct valuation peer.
ENOV	Comparable in market capitalization but focused on orthopedic technology, making its product economics and operating risks materially different from Omada's software-enabled care platform.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-12

Loading AI feed…

Symbol

Summary

ATEC

Similar-market-cap healthcare-equipment company, but its spine-device business has materially different demand, reimbursement, and product-cycle drivers; useful only as a broad growth-company reference.

CNMD

Similar-market-cap medical-device company with hospital and procedural exposure that differs substantially from Omada's virtual chronic-care model; not a direct valuation peer.

ENOV

Comparable in market capitalization but focused on orthopedic technology, making its product economics and operating risks materially different from Omada's software-enabled care platform.